Asclepii
Asclepii is a biomedical engineering company dedicated to revolutionizing regenerative medicine with a focus on making advanced therapies globally accessible and affordable. Founded by Franco Kraiselburd, the company develops innovative solutions such as Artemis™, a scalable tissue regeneration matrix that aims to transform wound care and organ manufacturing. With a mission to reduce costs and improve patient outcomes, Asclepii leverages cutting-edge research and global partnerships to scale its impact.
Industries
Nr. of Employees
small (1-50)
Products
Platform tissue-regeneration matrix (scaffold)
A hyper-scalable, collagen-enriched porous 3D extracellular matrix designed for wound healing and as a scaffold for cell or blood-based therapies; formulated for ambient storage and for incorporation of therapeutic additives.
Simplified cellular therapy format (point-of-care)
A simplified cell-therapy product format engineered for use with scaffold platforms to enable on-site or decentralized administration workflows.
Sensor-integrated monitoring dressing
Sensor modules embedded into scaffold materials to generate real-time physiologic data from wounds, feeding analytics pipelines for monitoring and clinical decision support.
Platform tissue-regeneration matrix (scaffold)
A hyper-scalable, collagen-enriched porous 3D extracellular matrix designed for wound healing and as a scaffold for cell or blood-based therapies; formulated for ambient storage and for incorporation of therapeutic additives.
Simplified cellular therapy format (point-of-care)
A simplified cell-therapy product format engineered for use with scaffold platforms to enable on-site or decentralized administration workflows.
Sensor-integrated monitoring dressing
Sensor modules embedded into scaffold materials to generate real-time physiologic data from wounds, feeding analytics pipelines for monitoring and clinical decision support.
Services
Design and support of early clinical evaluations and patient-use studies, and clinical affairs advisory services for wound-care and regenerative products.
Regulatory consulting focused on U.S. regulatory pathway planning and preparation of data and testing strategies for product approval.
Partnership development and process support for scaling production, regional manufacturing, and distribution agreements.
Collaborative research programs with universities and research centers to advance biomaterials, cell therapy integration and translational development.
Design and support of early clinical evaluations and patient-use studies, and clinical affairs advisory services for wound-care and regenerative products.
Regulatory consulting focused on U.S. regulatory pathway planning and preparation of data and testing strategies for product approval.
Partnership development and process support for scaling production, regional manufacturing, and distribution agreements.
Collaborative research programs with universities and research centers to advance biomaterials, cell therapy integration and translational development.
Expertise Areas
- Tissue engineering and regenerative medicine
- Wound care therapeutics and chronic wound management
- Biomaterials formulation and scaffold design
- Biomanufacturing scale-up and process development
Key Technologies
- Extracellular matrix scaffolds
- Collagen-enriched porous 3D matrices
- Semi-synthetic and stabilized biomaterial formulations
- Localized drug-delivery from scaffold matrices
News & Updates
21-year-old CEO seeks to revolutionize wound care industry
Franco Kraiselburd, at age 21, is working on Artemis™, a platform to reduce the cost of regenerative therapies from $30,000 to $300, aiming to treat chronic wounds and diabetic foot ulcers.
Innovación Biotecnológica: CEO de Asclepii busca nuevas colaboraciones con investigadores de la UV
Franco Kraiselburd visited the University of Valparaíso to explore collaboration opportunities to develop accessible and revolutionary medical therapies.
CWRU senior to showcase Asclepii at the prestigious festival’s 15th annual pitch competition
Franco Kraiselburd, a biomedical engineering student at Case Western Reserve University, is a finalist at SXSW Pitch 2024, showcasing innovations in tissue engineering.
Asclepii CEO Named MIT Innovator Under 35 & Pioneer of the Year (2024)
Franco Kraiselburd received the MIT Technology Review award as a young innovator for his work on scalable regenerative medicine solutions.
Franco Kraiselburd — Building the Next Generation of Tissue Engineering and Regenerative Cell Therapeutics to Improve Human Health
An in-depth profile of Franco Kraiselburd, his background, and his work on Artemis™ and regenerative medicine.
21-year-old CEO seeks to revolutionize wound care industry
A profile of Franco Kraiselburd and his company Asclepii, focusing on affordable regenerative therapies.
21-year-old CEO seeks to revolutionize wound care industry
Franco Kraiselburd, at age 21, is working on Artemis™, a platform to reduce the cost of regenerative therapies from $30,000 to $300, aiming to treat chronic wounds and diabetic foot ulcers.
Innovación Biotecnológica: CEO de Asclepii busca nuevas colaboraciones con investigadores de la UV
Franco Kraiselburd visited the University of Valparaíso to explore collaboration opportunities to develop accessible and revolutionary medical therapies.
CWRU senior to showcase Asclepii at the prestigious festival’s 15th annual pitch competition
Franco Kraiselburd, a biomedical engineering student at Case Western Reserve University, is a finalist at SXSW Pitch 2024, showcasing innovations in tissue engineering.
Asclepii CEO Named MIT Innovator Under 35 & Pioneer of the Year (2024)
Franco Kraiselburd received the MIT Technology Review award as a young innovator for his work on scalable regenerative medicine solutions.
Franco Kraiselburd — Building the Next Generation of Tissue Engineering and Regenerative Cell Therapeutics to Improve Human Health
An in-depth profile of Franco Kraiselburd, his background, and his work on Artemis™ and regenerative medicine.
21-year-old CEO seeks to revolutionize wound care industry
A profile of Franco Kraiselburd and his company Asclepii, focusing on affordable regenerative therapies.